{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T19:11:22Z","timestamp":1715713882685},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s00108-013-3336-2","type":"journal-article","created":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T08:34:36Z","timestamp":1373963676000},"page":"963-977","source":"Crossref","is-referenced-by-count":6,"title":["Das multiple Myelom","Multiple myeloma"],"prefix":"10.1007","volume":"54","author":[{"given":"K.M.","family":"Kort\u00fcm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,18]]},"reference":[{"key":"3336_CR1","unstructured":"Katalinic A, Pritzkuleit R (2013) Hochrechnung des Instituts f\u00fcr Krebsepidemiologie e.\u00a0V., L\u00fcbeck f\u00fcr ICD-10: C90 auf Basis der Daten der Krebsregister BY, BR, HB, HH, MV, NI, NW (Reg.-bez. M\u00fcnster), SL, SN, SH (2005\u20132009) mit einer Bezugsbev\u00f6lkerung von etwa 38\u00a0Mio. Menschen (46\u2009% der Gesamtbev\u00f6lkerung), n\u00e4here Angaben zur Methodik s.\u00a0auch http:\/\/www.gekid.de"},{"key":"3336_CR2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/leu.2011.368","volume":"26","author":"Greenberg","year":"2012","unstructured":"Greenberg AJ, Vachon CM, Rajkumar SV (2012) Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia 26:609\u2013614","journal-title":"Leukemia"},{"key":"3336_CR3","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"Landgren","year":"2009","unstructured":"Landgren O, Kyle RA, Pfeiffer RM et\u00a0al (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:5412\u20135417","journal-title":"Blood"},{"key":"3336_CR4","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"Weiss","year":"2009","unstructured":"Weiss BM, Abadie J, Verma P et\u00a0al (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:5418\u20135422","journal-title":"Blood"},{"key":"3336_CR5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International","year":"2003","unstructured":"International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749\u2013757","journal-title":"Br J Haematol"},{"key":"3336_CR6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00277-011-1293-1","volume":"91","author":"Eisele","year":"2012","unstructured":"Eisele L, Durig J, Huttmann A et\u00a0al (2012) Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann Hematol 91:243\u2013248","journal-title":"Ann Hematol"},{"key":"3336_CR7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4065\/mcp.2010.0520","volume":"85","author":"Rajkumar","year":"2010","unstructured":"Rajkumar SV, Kyle RA, Buadi FK (2010) Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 85:945\u2013948","journal-title":"Mayo Clin Proc"},{"key":"3336_CR8","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","volume":"375","author":"Dispenzieri","year":"2010","unstructured":"Dispenzieri A, Katzmann JA, Kyle RA et\u00a0al (2010) Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 375:1721\u20131728","journal-title":"Lancet"},{"key":"3336_CR9","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV et\u00a0al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N\u00a0Engl J Med 346:564\u2013569","DOI":"10.1056\/NEJMoa01133202"},{"key":"3336_CR10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2010.11.003","volume":"48","author":"Zingone","year":"2011","unstructured":"Zingone A, Kuehl WM (2011) Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol 48:4\u201312","journal-title":"Semin Hematol"},{"key":"3336_CR11","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2003-03-0801","volume":"102","author":"Kyle","year":"2003","unstructured":"Kyle RA, Therneau TM, Rajkumar SV et\u00a0al (2003) Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 102:3759\u20133764","journal-title":"Blood"},{"key":"3336_CR12","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"Kyle","year":"2010","unstructured":"Kyle RA, Durie BG, Rajkumar SV et\u00a0al (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121\u20131127","journal-title":"Leukemia"},{"key":"3336_CR13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2141.2010.08207.x","volume":"150","author":"Berenson","year":"2010","unstructured":"Berenson JR, Anderson KC, Audell RA et\u00a0al (2010) Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 150:28\u201338","journal-title":"Br J Haematol"},{"key":"3336_CR14","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","volume":"108","author":"Merlini","year":"2006","unstructured":"Merlini G, Stone MJ (2006) Dangerous small B-cell clones. Blood 108:2520\u20132530","journal-title":"Blood"},{"key":"3336_CR15","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","volume":"120","author":"Leung","year":"2012","unstructured":"Leung N, Bridoux F, Hutchison CA et\u00a0al (2012) Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 120:4292\u20134295","journal-title":"Blood"},{"key":"3336_CR16","doi-asserted-by":"crossref","unstructured":"Weber D, Rankin K, Gavino M et\u00a0al (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J\u00a0Clin Oncol 21:16\u201319","DOI":"10.1200\/JCO.2003.03.139"},{"key":"3336_CR17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE et\u00a0al (2003) Review of 1027\u00a0patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21\u201333","journal-title":"Mayo Clin Proc"},{"key":"3336_CR18","doi-asserted-by":"crossref","unstructured":"Blade J, Fernandez de Larrea C, Rosinol L et\u00a0al (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J\u00a0Clin Oncol 29:3805\u20133812","DOI":"10.1200\/JCO.2011.34.9290"},{"key":"3336_CR19","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood.V96.6.2037","volume":"96","author":"Dimopoulos","year":"2000","unstructured":"Dimopoulos MA, Moulopoulos LA, Maniatis A et\u00a0al (2000) Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 96:2037\u20132044","journal-title":"Blood"},{"key":"3336_CR20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ajh.22050","volume":"86","author":"Dispenzieri","year":"2011","unstructured":"Dispenzieri A (2011) POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86:591\u2013601","journal-title":"Am J Hematol"},{"key":"3336_CR21","doi-asserted-by":"crossref","unstructured":"Greipp PR, San Miguel J, Durie BG et\u00a0al (2005) International staging system for multiple myeloma. J\u00a0Clin Oncol 23:3412\u20133420","DOI":"10.1200\/JCO.2005.04.242"},{"key":"3336_CR22","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","volume":"23","author":"Fonseca","year":"2009","unstructured":"Fonseca R, Bergsagel PL, Drach J et\u00a0al (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23:2210\u20132221","journal-title":"Leukemia"},{"key":"3336_CR23","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","volume":"120","author":"Egan","year":"2012","unstructured":"Egan JB, Shi CX, Tembe W et\u00a0al (2012) Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 120:1060\u20131066","journal-title":"Blood"},{"key":"3336_CR24","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","volume":"120","author":"Keats","year":"2012","unstructured":"Keats JJ, Chesi M, Egan JB et\u00a0al (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120:1067\u20131076","journal-title":"Blood"},{"key":"3336_CR25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","volume":"138","author":"Barlogie","year":"2007","unstructured":"Barlogie B, Anaissie E, Rhee F van et\u00a0al (2007) Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy\u00a03. Br J Haematol 138:176\u2013185","journal-title":"Br J Haematol"},{"key":"3336_CR26","doi-asserted-by":"crossref","unstructured":"Attal M, Harousseau JL, Facon T et\u00a0al (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N\u00a0Engl J Med 349:2495\u20132502","DOI":"10.1056\/NEJMoa032290"},{"key":"3336_CR27","doi-asserted-by":"crossref","unstructured":"Cavo M, Tosi P, Zamagni E et\u00a0al (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna\u00a096 clinical study. J\u00a0Clin Oncol 25:2434\u20132441","DOI":"10.1200\/JCO.2006.10.2509"},{"key":"3336_CR28","doi-asserted-by":"crossref","unstructured":"McCarthy PL (2013) Part\u00a0I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. J\u00a0Natl Compr Canc Netw 11:35\u201342","DOI":"10.6004\/jnccn.2013.0006"},{"key":"3336_CR29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2141.2003.04299.x","volume":"121","author":"Einsele","year":"2003","unstructured":"Einsele H, Schafer HJ, Hebart H et\u00a0al (2003) Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 121:411\u2013418","journal-title":"Br J Haematol"},{"key":"3336_CR30","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","volume":"112","author":"Rosinol","year":"2008","unstructured":"Rosinol L, Perez-Simon JA, Sureda A et\u00a0al (2008) A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112:3591\u20133593","journal-title":"Blood"},{"key":"3336_CR31","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/sj.bmt.1704713","volume":"34","author":"Zeiser","year":"2004","unstructured":"Zeiser R, Deschler B, Bertz H et\u00a0al (2004) Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant 34:1057\u20131065","journal-title":"Bone Marrow Transplant"},{"key":"3336_CR32","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","volume":"22","author":"Dimopoulos","year":"2008","unstructured":"Dimopoulos MA, Kastritis E, Rosinol L et\u00a0al (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485\u20131493","journal-title":"Leukemia"},{"key":"3336_CR33","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS et\u00a0al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"key":"3336_CR34","unstructured":"(o\u00a0A) (2013) MM-Pathway, Version\u00a03, 6\/2013. Das Blaue Buch, 5.\u00a0Aufl. Springer (in Vorbereitung)"},{"key":"3336_CR35","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood-2012-10-435750","volume":"121","author":"Terpos","year":"2013","unstructured":"Terpos\u00a0E, Roodman GD, Dimopoulos MA (2013) Optimal use of bisphosphonates in patients with multiple myeloma. Blood 121:3325\u20133328","journal-title":"Blood"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-013-3336-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-013-3336-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-013-3336-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T18:47:03Z","timestamp":1715712423000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-013-3336-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,18]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["3336"],"URL":"https:\/\/doi.org\/10.1007\/s00108-013-3336-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,18]]}}}